Introduction

Headache is one of the most common disorders occurring in developmental ages. The prevalence of primary headaches ranges from 10% to 20% in school-children, and increases with age: 27%-32% of adolescents (13–14 years of age) experience headache once a month, and 87%-94% suffer headache at least once per year. No sex difference is apparent until age 11 years. Female preponderance begins at about age 12 years, and during and after adolescence the female-male ratio is about 2 to 1 [1]. The prevalence of migraine also increases with age, and estimates range from 1.2% to 3.2% at age 7 years and 4%-19% at age 15 years [2–5]. Age-related characteristics need to be taken into account in analyzing etiology, diagnosis and treatment of juvenile headache.

Many topics remain to be detected in childhood and adolescent headache [1], and these aspects should be considered in the implementation of trials on drug treatment, because it may help to avoid unexpected results.

The employment of International Headache Society (IHS) [6] criteria has shown limitations of applicability in childhood headache. Modifications to the diagnostic para-
meters have been discussed both for migraine and tension-type headache [7–15]. The suggested changes to IHS criteria for the diagnosis of migraine in children refer to shorter duration, not always unilateral localization, and the variable occurrence of photophobia and phonophobia. Interestingly, over time (even at a brief follow-up period) there is a decreased symptoms overlap and a better fulfilment of IHS diagnostic parameters, stressing the role of increasing age to the better fulfilment of the criteria [15].

A recent follow-up study [15] of patients initially classified as IHS 1.7 (patients who meet all criteria for migraine but one) and 2.3 (patients who meet all criteria for tension-type but one) showed that, after a brief follow-up period (1.5 years), nearly 30% became headache-free, about 20% changed IHS category, and the remaining 50% became migraine or tension-type headache sufferers, as shown by previous outcome studies [16, 17].

The tendency of migraine to spontaneous remission and the clinical phenomenology of the crises during development ages should be considered in the analysis and implementation of controlled trials.

A rational drug therapy in children and adolescents requires individualized treatments, recognizing individual (age, comorbid disorders, concurrent medications), developmental (pharmacodynamic, pharmacokinetic, pharmacogenetic) and environmental (diet, obstacles to compliance) factors that can influence disposition and response to treatment. Stage of development markedly influences the absorption, distribution, metabolism and excretion of drugs [18]. Agents that work well in adults may provoke different reactions in children. Safety and tolerability issues need specific attention, not simple transposition from adult to child or adolescent field. The “whole” always differs from the single sum of each part.

Several aspects differentiating children and adolescents from adults should be taken into account in planning a rational drug treatment. Taking into consideration these differential factors is even the sine qua non of the implementation of controlled trials on drug responses in children and adolescents.

**Triptans in children and adolescents: state of the art**

The advent of triptans is considered a revolution in the current approach to acute migraine treatment [19]. The importance of studies on triptans concerns both the efficacy of the drugs and the advancement of our understanding of the pathophysiology of migraine.

Triptans are 5-HT\textsubscript{1B/1D} agonists. Currently, sumatriptan and zolmitriptan are available, while naratriptan and rizatriptan are not yet available in all countries. The first triptan to be developed and most extensively used in adults is sumatriptan (GR43175, Imitrex). Triptans have proven effective in adults [20–27], but there are few clear data regarding the use of triptans in pediatric age.

For prepubertal age, data are scanty and relate particularly to sumatriptan, a triptan with a longer seniority of use. In the first balanced double-blind design, Hamalainen et al. [28] failed to prove any significant difference between drug and placebo. Probably children with migraine respond differently from adults to the oral administration of sumatriptan.

A recent trial [29] highlighted a promising response to sumatriptan nasal spray (sumatriptan NS 20 mg). Two hours after medication, a significant pain-free response and relief from associated symptoms was reported. A second study employed a prospective open design on a group of 58 children (mean age, 8.1 years) [30]. Of 376 attacks treated, sumatriptan NS reduced migraine pain in 80% of the cases, nausea in 78%, vomiting in 82%, and phonophobia and photophobia in 63%; there was an overall clinical improvement in 79% of cases. The tolerability overlapped with that observed in adults.

Data relating to the use of triptans in adolescents are, in part, still unclear. The profile studies (balanced double-blind design on 701 patients aged 12–17 years) supplied by the pharmaceutical company with regard to sumatriptan seem quite conservative [31, 32]. No significant efficacy of sumatriptan versus placebo has been observed. Furthermore, the sample showed a significantly lower tolerance than the group of adult patients.

In two recent studies of sumatriptan NS, one a multicentric open-label study [33] and the other a double-blind study versus placebo [34], sumatriptan was superior to placebo with regard to headache response and to the recovery of functional disability 2 hours after medication. The tolerability profiles thereby observed overlapped with those for adults. A recent open-label study [35] on zolmitriptan (Zomig) produced data of efficacy and tolerability which overlapped with those of adults. However, the drug’s half-life in adolescents was slightly lower than that in adult patients (3.01 h vs. 3.75 h), probably due to a higher clearance. For this reason, some authors deemed it advisable to use the lowest dosage (2.5 mg) when treating a pediatric population [36]. Another open-label study [37] reported a pain-free headache response 2 hours after medication, entirely overlapping with that already observed in adult subjects.

The occurrence of side effects and the tolerability profile in adolescent patients confirmed the overlap with the same parameters observed in adults. Typical adverse events for sumatriptan (subcutaneous) are hot/burning and pressure sensations, injection site reaction and muscle stiffness [38].
In general we may state that there is a lack of data from clinical trials on the use of triptans in the years of growth. It is also important, as already stated, to have available studies to clarify the pharmacodynamics and pharmacokinetics of triptans in patients in the years of growth. Data from the few available studies highlight that pharmacokinetic mechanisms of triptans in children seem to be different from what has been observed in the adult population. Sumatriptan is mainly metabolized by the enzyme MAO-A (monoamine oxidase A) in the liver [39], but the possible influences of age on the action of MAO-A are not known [28]. In adults, sumatriptan causes neuroendocrine changes (increased plasma growth hormone, possible effects on plasma prolactin) [40, 41], but the neuroendocrine influences in children or adolescents are not known.

The effect of age on pharmacokinetics of zolmitriptan metabolites has been recognized in a recent study on young and elderly adults [42]. The pharmacokinetics of naratriptan in adolescents showed parameters overlapping to those for adults [43].

Studies on subcutaneous sumatriptan [44, 45] showed good efficacy in 64%–84% of patients (6–18 years), but clear data on doses, tolerability and side effects are lacking.

Summing up, in the studies carried out so far and herein analyzed, triptans were effective for reducing migraine pain and symptoms associated with headache pain (e.g. nausea, vomiting, phonophobia, photophobia) and for decreasing the times needed to return to normal activities and for the remission of symptomatology. However, data about the primary efficacy of triptans (i.e. total remission of pain) are not yet sufficient. The tolerability and safety rates are comparable to those observed in adult patients. Side effects are the same in pediatric and adult populations. In light of the results already published in the literature, triptans can be used during pediatric age. However, while waiting for further support, priority use is advised only in those cases in which migraine pain is “hard” or “impossible” to treat with other analgesic drugs. The situation is different in adolescence, for which there are sufficient data suggesting the utility of triptans. It is furthermore advised to give parents and patients precise instructions on the use of triptans, information on the peculiarity of their side effects, and the more general specifications of the drug.

**Future directions**

Drug treatment in pediatric age should always take into account that age-related differences markedly influence the absorption, distribution, metabolism and excretion of drugs. Recognizing individual (age, comorbid disorders, psychological factors) and developmental (pharmacodynamic, pharmacokinetic, pharmacogenetic) factors that can influence disposition and response to the treatment is a pressing task, requiring pediatric age goal-directed studies.

Good results for the use of triptans in children and adolescents have emerged from open-label studies, but evidence from placebo-controlled, double-blind, randomized, crossover trials are absolutely required. Moreover, most data are available only in abstract form.

Clinical trials on pediatric patients are lacking, and the findings are unsatisfactory. There have been no clinical trials testing the efficacy of different triptans. Studies comparing the efficacy of triptans to that of other analgesic drugs with tested efficacy are also needed.

The effect of age in the proband samples should be considered with more attention, because samples usually comprise subjects of pre-pubertal and post-pubertal age.

The presence of “pure” and easily diagnosed migraine according to IHS criteria, instead of mixed types or forms intercalated to (episodic or chronic) tension-type headache, should be carefully assessed, because it may represent factors influencing the efficacy of the triptan.

Analyzing the characteristics of non-responders is another issue to consider in order to understand factors influencing drug efficacy and tolerability. The presence of psychiatric comorbidity should be assessed, also considering the negative implications for the prognosis [46].

Family and school environments, likely secondary gains related to migraine crises, may play an important role in influencing the course of the crises. Issues related to compliance should be carefully analyzed in children and adolescents. Indications for correct triptan intake should be absolutely given.

Another aspect that merits attention is the high rate of response to placebo, because it opens per se the importance of psychological factors in influencing head pain. Moreover, the response rate to placebo (vs. oral sumatriptan) seems to be lower in children [47] than in adolescents [28]. Studies on triptans of established efficacy in adults (most of all rizatriptan) [48–50] are absolutely lacking for child and adolescent patients.

A better comprehension of the biological mechanisms related to the responses to placebo (“how does placebo really work?”) and the likely influence of age on it may help explain the etiopathogenesis of migraine.

In extreme synthesis, the current state of research on the use of triptans for child and adolescent migraine does not lead to definitive conclusions. Many points need further examination towards the objective of giving “the best drug to each patient” according to the individual characteristics. Clearly, that issue assumes particular shadows in children and adolescents, for whom personal characteristics (e.g. biological, psychological) are strictly embedded with the clinical age-related phenomenology of headache crises, in a “crossing-over” of difficult framing and decoding.
References

1. Guidetti V, Galli F (2001) Recent development in paediatric headache. Curr Opin Neurol 14:355–340
2. Mortimer J, Kay J,aron A (1992) Epidemiology of headache and childhood migraine in an urban general practice using ad hoc, Vahlaquist and IHS criteria. Dev Med Child Neurol 34:1095–1101
3. Sillanpaa M, Piekalka P, Kero P (1991) Prevalence of headaches at preschool age in unselected child population. Cephalalgia 11:239–242
4. Sillanpaa M (1983) Changes in the prevalence of migraine and other headaches during the first seven school years. Headache 23:15–19
5. Deubner DC (1977) An epidemiologic study of migraine and headache in 10–20 year old. Headache 17:137–180
6. International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 8(Suppl 7):1–96
7. Guidetti V, Bruni O, Cerutti R et al (1991) How and why childhood headache and migraine differ from that of the adults. In: Gallai V, Guidetti V (eds) Juvenile headache. Excerpta Medica, Amsterdam, pp 27–32
8. Metsähonkala L, Sillanpää M (1994) Migraine in children – an evaluation of the IHS criteria. Cephalalgia 14:285–290
9. Winner P, Martinez W, Mate L, Bello E et al (1996) IHS criteria for migraine and tension-type headache in children at a headache clinic. Cephalalgia 15:404–409
10. Hamalainen ML, Hoppu K, Santavouri P (1995) Effect of age on the fulfilment of the IHS criteria for migraine in children at a headache clinic. Cephalalgia 15:404–409
11. Zebenholzer K, Wöber C, Kienbacher C, Wöber-Bingöl Ç (2000) Migrainous disorder and headache of the tension type not fulfilling the criteria: a follow-up study in children and adolescents. Cephalalgia 20:611–616
12. Dooley J, Bagnell A (1995) The prognosis and treatment of headaches in children - A ten-year follow-up. Can J Neurol Sci 22:47–49
13. Guidetti V, Galli F (1998) Evolution of headache in childhood and adolescence: an 8-year follow-up. Cephalalgia 18(7):450–454
14. Seshia SS (1996) Specificity of IHS criteria in childhood headache. Headache 36:231–238
15. Maytal J, Young M, Shechter A, Lipton RB (1997) Pediatric migraine and International Headache Society (IHS) criteria. Neurology 48:602–607
16. Maytal J, Young M, Shechter A, Lipton RB (1997) Pediatric migraine and International Headache Society (IHS) criteria. Neurology 48:602–607
17. Guidetti V, Galli F (1998) Evolution of headache in childhood and adolescence: an 8-year follow-up. Cephalalgia 18(7):450–454
18. Leeder JS, Kearnes GL (1997) Pharmacogenetics in pediatrics. Pediatr Clin North Am 44(1):55–77
19. Gawel MJ, Tepper SJ (1998) The triptan revolution. Semin Headache Management 3(1):4–5
20. Thomsen LL, Dixon R, Lassen Gibbens M, Langemark M, Bendtsen L, Daugaard D, Olesen J (1996) 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270–275
21. Zagami AS (1997) 311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group. Neurology 48(3 Suppl 3):S25–S28
22. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD (1996) 311C90, a new centrally and peripherally acting 5-hydroxytryptamine 1D receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 46(2):522–526
23. Geraud GE (1996) Evaluation of the IHS criteria. Cephalalgia 17(Suppl 18):28–40
24. Schoenen J, Sawyer J (1997) Zolmitriptan (Zomig, 311C90), a novel central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 17(Suppl 18):28–40
25. Paffenhoff V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38(3):184–190
26. Moschiano F, D’Amico D, Grazzi L, Leone M, Bussonne G (1997) Sumatriptan in the acute treatment of migraine without aura: efficacy of 50-mg dose. Headache 37(7):421–423
27. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B (1995) Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 45(Suppl 7):S15–S20
28. Hamalainen M, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: a randomized placebo controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 48:1100–1103
29. Ueberall MA, Wenzel D (1999) Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 52:1507–1510
30. Ueberall MA (1999) Nasal sumatriptan in prepubertal children with migraine. In: IV International Congress on Headache in Childhood and Adolescence, Turku, 2–4 September 1999 (abstract)
31. Imitrex nasal spray, product information; GlaxoWellcome, 1999
32. Imitrex tablets, product information; GlaxoWellcome, 1999
33. Rothner AD, Winner P, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M (2000) One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 22(12):1533–1546
34. Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M (2000) A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 106(5):989–997
35. Dowson AJ, Fletcher PE, Millson DS (1998) Efficacy and tolerability of “Zomig” in adolescent migraine. In: 12th Trust International Symposium, London, 1–4 September 1998

36. Dixon R, Engleman K, Kemp J, Ruckle JL (1999) A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol 9(1):35–42

37. Linder SL, Dowson AJ (2000) Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract 54(7):466–469

38. Evers S (1999) Drug treatment of migraine in children – A comparative review. Paediatr Drugs 1(1):7–18

39. Dixon CM, Park GR, Tarbit MH (1994) Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 47:1253–1257

40. Herdman JR, Delva NJ, Hockney RE, Campling GM, Cowen PJ (1994) Neuroendocrine effects of sumatriptan. Psychopharmacology 113(3–4):561–564

41. Boeles S, Williams C, Campling GM, Goodall EM, Cowen PJ (1997) Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology 129(2):179–182

42. Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SH, Rollan PE, Posner J (1998) The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 63(3):342–353

43. Christensen ML, Eades SK, Fuseau E, Kempford RD, Phelps SJ, Hak LJ (2001) Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. J Clin Pharmacol 41(2):170–175

44. MacDonald JT (1994) Treatment of juvenile migraine with subcutaneous sumatriptan. Headache 34:581–582

45. Linder SL (1996) Subcutaneous sumatriptan in the clinical setting: the first consecutive patients with acute migraine in a pediatric neurology office practice. Headache 36:419–422

46. Guidetti V, Galli F, Fabrizi P, Napoli L, Giannantoni AS, Bruni O, Trillo S (1998) Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study. Cephalalgia 18(7):455–462

47. Korsgaard AG (1995) The tolerability, safety, and efficacy of oral sumatriptan 50 mg and 100 mg for the acute treatment of migraine in adolescents. Presented at the 3rd International Congress on Headache in Childhood and Adolescence, May 4–6, Budapest

48. Tfelt-Hansen P, Goldstein J, Malbecq W, Lines C (1997) Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 38(10):737–747

49. Silberstein SD (2000) Rizatriptan versus usual care in long-term treatment of migraine. Neurology 55(9 Suppl 2):S29–S35

50. Gobel H, Heinze A, Heinze-Kuhn K, Lindner V (2001) Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70527 patient episodes. Headache 41(3):264–270